What is the story about?
Zydus Lifesciences Ltd. on Thursday, January 15, informed stock exchanges that it has secured final approval from the US Food and Drug Administration for Eltrombopag Tablets in strengths of 12.5 mg, 25 mg, 50 mg and 75 mg.
Eltrombopag is used to treat thrombocytopenia, or low platelet count, associated with certain blood disorders.
The drug works by stimulating bone marrow cells to increase platelet production, helping lower the risk of bleeding.
The tablets will be manufactured at the group's SEZ formulation facility in Ahmedabad.
In the US market, Eltrombopag recorded annual sales of $1,262.5 million as per IQVIA MAT data for November 2025.
With this approval, the group's cumulative USFDA approvals stand at 429, while it has filed a total of 505 ANDAs since it began filings in FY2003-04.
Shares of Zydus Lifesciences Ltd. settled 1.74% lower on Wednesday at ₹ 885..
Eltrombopag is used to treat thrombocytopenia, or low platelet count, associated with certain blood disorders.
The drug works by stimulating bone marrow cells to increase platelet production, helping lower the risk of bleeding.
The tablets will be manufactured at the group's SEZ formulation facility in Ahmedabad.
In the US market, Eltrombopag recorded annual sales of $1,262.5 million as per IQVIA MAT data for November 2025.
With this approval, the group's cumulative USFDA approvals stand at 429, while it has filed a total of 505 ANDAs since it began filings in FY2003-04.
Shares of Zydus Lifesciences Ltd. settled 1.74% lower on Wednesday at ₹ 885..
